Despite deaths, docs and patients sticking with Medtronic pump

Medtronic ($MDT) has issued repeated warnings about its SynchroMed line of implanted infusion pumps, detailing problems that have led to 14 deaths since 1996. But despite those concerns, doctors and patients told the Minneapolis Star-Tribune that SynchroMed's benefits still outweigh its risks, and many are holding tight until problems with their specific implants arise. Article

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.